Patient info Open main menu

Deferiprone Lipomed 500 mg film-coated tablets – patient leaflet, side effects, dosage

Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
500 mg
Contains active substance:

Patient leaflet - Deferiprone Lipomed 500 mg film-coated tablets

1. What Deferiprone Lip is used for

  1. 2.

    What you need to kno

    for you.

    may need to read it again. r questions, ask your doctor

    en prescribed for you only. thers. It may harm them, even are the same as yours. ects, talk to your doctor or des any possible side effects t. See section 4.

    g box, you will find a patient plete and read the card with you. Provide this card develop infection symptoms hroat or flu-like symptoms.

    omed is and what it

    w before you take

    Deferipone Lipomed

  2. 3. How to take Deferipro
  3. 4. Possible side effects
  4. 5. How to store Deferipr
  5. 6. Contents of the pack
  6. 1. What Deferiprone it is used for

Deferiprone Lipomed co deferiprone. Deferipron a type of medicine that the body.

Deferiprone Lipomed is caused by frequent bloo with thalassaemia majo therapy is contraindicat

ne Lipomed

one Lipomed

and other information

Lipomed is and what

ntains the active substance e Lipomed is an iron chelator, removes excess iron from

used to treat iron overload d transfusions in patients r when current chelation ed or inadequate.

2. What you need to Deferiprone Lipo

Do not take Deferipro

  • if you are allergic to d ingredients of this me • if you have a history o neutropenia (low whi count);
  • if you have a history o white blood cell (neut • if you are currently ta cause neutropenia or medicines and Deferi
  • if you are pregnant or

    know before you take med

    ne Lipomed

    eferiprone or any of the other dicine (listed in section 6); f repeated episodes of te blood cell (neutrophil)

    f agranulocytosis (very low rophil) count);

    king medicines known to agranulocytosis (see «Other prone Lipomed»);

    breast-feeding.

    Warnings and precaution

    The most serious side effec taking Deferiprone Lipome blood cell (neutrophil) cou as severe neutropenia or ag occurred in 1 to 2 out of 10 deferiprone in clinical trials cells help to fight infection, may place you at risk of dev potentially life-threatening neutropenia, your doctor w

    s

    t that may occur while d is a very low white nt. This condition, known ranulocytosis, has

    0 people who have taken . Because white blood a low neutrophil count eloping a serious and infection. To monitor for ill ask you to have a blood test (to check your white bl regularly, as frequently as e being treated with Deferipr important for you to keep a Please refer to the patient c folding box. If you get any s such as fever, sore throat or immediately seek medical blood cell count must be c order to detect potential ag

    If you are HIV positive or if function is severely impaire recommend additional test

    Your doctor will also ask yo monitor body iron load. In ask you to undergo liver bi

    Talk to your doctor or phar

    ood cell count) performed very week, while you are one Lipomed. It is very ll of these appointments. ard provided in the ymptoms of infection flu-like symptoms, attention. Your white hecked within 24 hours in ranulocytosis.

    your liver or kidney d, your doctor may s.

    u to come in for tests to addition, he or she might opsies.

    macist before taking

    Deferiprone Lipomed.

    Other medicines and Def

    Do not take medicines kno or agranulocytosis (see «Do Lipomed»). Tell your doctor taking, have recently taken medicines, including medic prescription.

    Do not take aluminium-bas time as taking Deferiprone

    Please consult with your do taking vitamin C with Defer

    Pregnancy and breast-fe

    Deferiprone Lipomed may babies when used by pregn Lipomed must not be used

    eriprone Lipomed wn to cause neutropenia not take Deferiprone or pharmacist if you are , or might take any other ines obtained without a ed antacids at the same Lipomed.

    ctor or pharmacist before iprone Lipomed.

    eding

    cause harm to unborn ant women. Deferiprone during pregnancy unless clearly necessary. If y become pregnant during tr Lipomed, get medical advi

    Both female and male patie to take special precautions if there is any possibility for Women of childbearing po to use effective contracepti Deferiprone Lipomed and f last dose. Men are recomm contraception during treat after the last dose. This sho doctor.

    Do not use Deferiprone Lip feeding. Please refer to the the folding box.

    ou are pregnant or you eatment with Deferiprone ce immediately.

    nts are recommended in their sexual activity pregnancy to occur. tential are recommended on during treatment with or 6 months after the ended to use effective ment and for 3 months uld be discussed with your omed if you are breast-patient card provided in

    Driving and using machines

    This medicine has no or neglig ability to drive and use machin

    Deferiprone Lipomed contai

    This medicine contains less th (23 mg) per tablet and that is t ‘sodium-free’.

3. How to take Deferipron

ible influence on the ery.

ns sodium an 1 mmol sodium

o say essentially e Lipomed

Always take this medicine exa told you. Check with your doct are not sure. The amount of D that you take will depend on y usual dose is 25 mg/kg, 3 time daily dose of 75 mg/kg. The to not exceed 100 mg/kg. Take yo morning. Take your second do third dose in the evening. Defe be taken with or without food; it easier to remember to take D if you take it with your meals.

If you take more Deferipron you should

There are no reports of acute o deferiprone. If you have accide the prescribed dose, you shou

ctly as your doctor has or or pharmacist if you eferiprone Lipomed our weight. The s per day, for a total tal daily dose should ur first dose in the se midday. Take your riprone Lipomed can however, you may find eferiprone Lipomed e Lipomed than verdose with ntally taken more than ld contact your doctor.

If you forget to take Deferip

Deferiprone Lipomed will be m do not miss any doses. If you d it as soon as you remember an at its regularly scheduled time one dose do not take a double forgotten individual doses, jus normal schedule. Do not chan without first talking to your do

4. Possible side effects

Like all medicines, this medicin effects, although not everybo

The most serious side effect of is a very low white blood cell ( This condition, known as sever agranulocytosis, has occurred i

rone Lipomed ost effective if you

o miss one dose take d take your next dose . If you miss more than dose to make up for t continue with your ge your daily dose ctor.

e can cause side dy gets them.

Deferiprone Lipomed neutrophil) count. e neutropenia or n 1 to 2 out of 100 people who have taken deferiprone in white blood cell count can be a and potentially life-threatenin immediately to your doctor an such as: fever, sore throat or flu

Very common side effects

(may affect more than 1 in 10 p • abdominal pain

  • nausea
  • vomiting
  • reddish/brown discolourati

If you experience nausea or vo to take your Deferiprone Lipo Discoloured urine is a very com is not harmful.

clinical trials. A low ssociated with a serious g infection. Report y symptoms of infection -like symptoms.

eople):

on of urine miting, it may help med with some food. mon effect and

Rohformat: 240 x 280 mm / Endformat gefalzt: 40 x 70 mm

Common side effects

(may affect up to 1 in 10 • low white blood cell c and neutropenia) • headache

  • diarrhoea
  • increase in liver enzy • fatigue
  • increase in appetite

Not known

people):

ount (agranulocytosis

mes

(frequency cannot be es data):

  • allergic reactions incl

Events of joint pain and pain in one or more join cases, the pain disappea taking deferiprone.

Additional side effects

In post-marketing exper neurological disorders ( disorders, double vision contractions, problems have been reported in c voluntarily prescribed m maximum recommende for several years and ha children with standard d recovered from these sy

timated from the available

uding skin rash or hives

swelling ranged from mild ts to severe disability. In most red while patients continued

in children

ience with deferiprone, such as tremors, walking , involuntary muscle

with movement coordination) hildren who had been

ore than double the

d dose of 100 mg/kg/day ve also been observed in oses of deferiprone. They mptoms after discontinuation

of deferiprone.

Reporting of side effec

If you get any side effec pharmacist or nurse. Thi effects not listed in this side effects directly via t Website: www.mhra.go MHRA Yellow Card in th Store. By reporting side more information on th

5. How to store Defe

Keep this medicine out children.

Do not store above 25 °

ts

ts, talk to your doctor, s includes any possible side leaflet. You can also report he Yellow Card Scheme v.uk/yellowcard or search for e Google Play or Apple App effects, you can help provide e safety of this medicine.

riprone Lipomed

of the sight and reach of

C.

Do not use this medicin is stated on the carton a The expiry date refers to

Do not throw away any household waste. Ask y away medicines you no will help protect the env

  1. 6. Contents of the p information

What Deferiprone Lip

The active substance is tablet contains 500 mg

e after the expiry date which nd on the blister after EXP. the last day of that month.

medicines via wastewater or our pharmacist how to throw longer use. These measures ironment.

ack and other

omed contains

deferiprone. Each film-coated deferiprone.

The other ingredients are:

Tablet core: hypromellose, (see section 2 «Deferiprone sodium»), silica, colloidal an cellulose, magnesium stear

Coating: hypromellose, ma dioxide

What Deferiprone Lipom

croscarmellose sodium Lipomed contains hydrous, microcrystalline ate

crogol 6 000, titanium ed looks like and

contents of the pack

Deferiprone Lipomed 500 white to off-white, glossy s tablets. The tablets are scor Deferiprone Lipomed is pa pack contains 100 film-coat

Marketing Authorisation Manufacturer

Lipomed GmbH

Hegenheimer Strasse 2 79576 Weil am Rhein Germany

Phone number: +49 7621 1 Fax number: +49 7621 1693 Electronic mail: lipomed@li

This leaflet was last revis

mg film-coated tablets are urface, oval film-coated ed and breakable in half. ckaged in blisters. One ed tablets.

Holder and

693 472

474

pomed.com

ed in May 2023.

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 19745/0005

MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Deferiprone Lipomed 500 mg film-coated tablets

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Deferiprone
Strength 500 mg
Pharmaceutical form Oral tablet
White to off-white, glossy surface, oval film-coated tablet. The tablet is 8.2 mm x 17.2 mm x 6.7 mm and scored. The tablet can be divided into equal doses.
How is it taken Oral
Excipients Hypromellose, Croscarmellose sodium, Silica, colloidal anhydrous, Microcrystalline cellulose, Magnesium stearate, Macrogol 6 000, Titanium dioxide
Pack sizes 100 tablet
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life 5 years.
Storage Do not store above 25°C.
Drug group (ATC) All other therapeutic products, iron chelating agents
  1. V Various drug classes
    1. V03 All other therapeutic products
      1. V03A All other therapeutic products
        1. V03AC Iron chelating agents
          1. V03AC02 deferiprone
Marketing authorisation PLGB 19745/0005 (first authorised 8 August 2023)
Marketing authorisation holder Lipomed GmbH
Codes GTIN 7629999696549 · BNF 09010300

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.